Early-Life Pancreas Development Offers Clues to More Aggressive Type 1 Diabetes in Young Children

As of 2025, a global estimate shows that there are about 9.5 million people living with type 1 diabetes (T1D), an incurable chronic condition in which the pancreas produces little or no insulin by itself, causing an average of 34 years of healthy life to be lost per person due to the disease. According to a major multi-biobank investigation recently published in Science Advances, a team of researchers from the University of Exeter Medical School has uncovered a structural vulnerability in the developing pancreas that may explain why T1D is more aggressive when it begins in young children.

The Underexplored World of Endocrine Objects

It is widely accepted that T1D is caused by an autoimmune reaction, leading to the destruction of insulin-making pancreatic beta cells. The process can last for months or even years before any symptoms appear. In particular, for young children, whose age of onset is under 7, T1D often progresses more rapidly, increasing the likelihood of medical emergencies and requiring greater insulin dosages than those diagnosed at an older age.

Funded by the Type 1 Diabetes Grand Challenge – a partnership between The Steve Morgan Foundation, Diabetes UK, and Breakthrough T1D, the team demonstrated that young children rely heavily on tiny, previously underappreciated clusters of β cells for pancreatic endocrine development. These structures, called endocrine objects (EOs) are abundant in healthy young donors but strikingly depleted in individuals with T1D, particularly those diagnosed before age 7.

Thanks to advances in 3D imaging modalities, scientists have identified these β-cell–rich EOs scattered throughout the pancreas, especially during early life. In the present study, the team analysed more than 450 slides of immunolabelled pancreas sections collected from 250 healthy and diabetic donors in multiple biobanks. This allowed researchers to quantify EO size, hormone composition, and spatial distribution across developmental time and in the presence or absence of T1D.

A Developmental Landscape Rich in Small β-Cell Clusters

One of the study’s most striking findings is the dominance of small EOs in early-life pancreas morphology. In donors without diabetes, the majority of pancreatic endocrine area in the first years of life is located not in large islets, but in these microstructures composed of single cells or tiny β-cell clusters. They serve as essential building blocks during postnatal endocrine expansion, reflecting a dynamic organ still assembling its mature architecture.

The abundance and distribution of these objects change significantly across childhood. In healthy tissue, small β-cell-rich clusters proliferate during infancy and begin consolidating into larger islets as the pancreas matures. “This new perspective has the potential to reshape how we screen, treat, and even prevent type 1 diabetes. Protecting small beta cell clusters early could be key to stopping type 1 diabetes before it starts,” said Professor Sarah Richardson, the leader of Exeter’s research team.

Type 1 Diabetes Wipes Out the Small β-Cell Reservoir

In contrast, researchers found that donors with T1D suffer a near-complete loss of these small insulin-positive EOs. The absence is consistent across disease duration and particularly profound in children diagnosed at the youngest ages. The authors describe small EOs as “virtually absent” in early-onset T1D, indicating that the autoimmune attack not only destroys classical islets but also eliminates those small β-cell clusters critical for early-life development. 

This depletion carries long-term consequences. When these foundational β-cell units are destroyed early, the pancreas loses both functional capacity and developmental potential. It cannot generate or expand larger islets later in life because the building blocks required for maturation have been removed.

Why Young Children Experience a More Severe Disease Course?

Clinicians have long observed that T1D diagnosed during very early childhood is more aggressive, and the structural findings from this study provide a mechanistic explanation. The immune attack occurring while the pancreas is still forming its endocrine architecture inflicts disproportionately greater damage than an equivalent autoimmune process occurring in adolescence or adulthood.

Children diagnosed when the small-cluster reservoir is still predominant have fewer remaining β-cell units to salvage, leading to faster decline in insulin production and a more unstable clinical course. While those type 1 diabetics of older age of onset often retain a few large clusters, allowing them to produce small amounts of insulin, this was not the case for those diagnosed at a young age. As summarized by Exeter’s press release, “In young children with type 1 diabetes, nearly all insulin-producing cells are destroyed before they can mature.”

A Case for Earlier Screening and Intervention

Because the study identifies a precise developmental window during which the pancreas is uniquely vulnerable, it strengthens the case for earlier risk detection. Autoantibody screening programs, particularly for families with known genetic risk, may need to emphasise the first five to seven years of life rather than waiting until adolescence.

The findings also support the strategic timing of emerging immunotherapies. If early-life pancreatic architecture can be preserved—even temporarily—patients might retain enough small EOs to allow normal endocrine maturation. In the video released by the University of Exeter (featuring members of the study team) one researcher states: “If we can buy the pancreas time to mature, we may prevent the full severity of the condition.” This aligns with the paper’s conclusion that newly developed drugs could buy patients time for the pancreas to mature. 

While the study itself does not test therapeutic interventions, it directly highlights the need to evaluate whether stabilising immune aggression in early childhood could preserve extra-islet β-cell units. Protecting these might enable children to reach a more resilient pancreatic architecture.

Broader Research Implications and Next Steps

The authors also note the limitations of rodent models for early-life pancreatic development, reinforcing the importance of human biobank networks. Unlike mice, which show different developmental architecture and EO prevalence, the human pancreas exhibits a complex and evolving pattern of microstructures that must be studied directly in human tissue. 

Regarding future research, some possible directions include determining whether EO loss precedes or follows islet-level destruction by immune attack in pre-clinical T1D, exploring specific immune-cell signatures which correlate with the preferential elimination of small β-cell clusters, and assessing the impact of immunomodulatory treatments on preserving EO populations during early childhood.

Related posts:

Newly Created Immune-Evading Human Islets Could Potentially Treat Diabetes U.S.-German Joint Discovery May Spark Breakthrough in Diabetes Research World Diabetes Day 2025: Turning Awareness into Actions Across Life Stages and Workplaces 2024 Top 10 Diabetes Drugs and Promising Type 1 Treatments to Watch

Author

Richard Chau